Allurion Technologies 執行反向股票分割以符合上市要求
Allurion Technologies performs reverse stock split to meet listing requirements
Updated at: June 18, 2026 at 12:45 AM
Allurion Technologies(阿盧瑞科技)這家醫療設備公司，以其創新且無須手術的胃部減重氣球而聞名。
Allurion Technologies, a medical device company best known for its innovative, procedure-less swallowable gastric balloon for weight loss, has recently taken significant financial steps to remain listed on major stock exchanges.
該公司近期採取了重大的財務措施，以維持其在主要證券交易所的上市地位。
Like many small-cap companies facing price volatility, Allurion has used reverse stock splits to consolidate its shares and boost its market price.
與許多面臨股價波動的小型股公司一樣，Allurion 採用了股份合併（又稱反向拆股）來整併股票並提升市場價格。
In January 2025, the company implemented a 1-for-25 reverse split to address concerns regarding the New York Stock Exchange's minimum bid price requirements.
2025 年 1 月，該公司實施了 1 股換 25 股的反向拆股，以應對紐約證券交易所對最低報價的相關顧慮。
Following further market pressure, Allurion executed another reverse split on June 18, 2026, this time at a 1-for-15 ratio.
雖然這些企業行動屬於技術層面（涉及股權獎勵和認股權證的調整），但它們凸顯了 Allurion 所面臨的營運挑戰，包括營收縮減以及加強整體資本市場地位的需求。
By consolidating its stock, the company hopes to improve its visibility and meet the rigorous mandates required to stay on the exchange.
透過股份合併，公司希望能提升其市場能見度，並達成留在交易所所需的嚴格規定。
